Skip to main content
. 2020 Aug 15;4(6):1135–1139. doi: 10.1002/jgh3.12408

Figure 2.

Figure 2

Representative case of a 77‐year‐old male with unresectable hepatocellular carcinoma treated with sorafenib after progression on lenvatinib. (a) A contrast‐enhanced computed tomography examination after lenvatinib failure showed multiple enhanced lesions. (b) Enhancement lesions were decreased at 8 weeks after the administration of sorafenib.